Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS)
CNY 16.88
(-0.3%)
CNY 16.88
(-0.3%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 179.16 Million CNY | -24.3% |
| 2022 | 236.66 Million CNY | 29.04% |
| 2021 | 183.4 Million CNY | 59.34% |
| 2020 | 115.1 Million CNY | 12.29% |
| 2019 | 102.5 Million CNY | 23.15% |
| 2018 | 83.23 Million CNY | 9.95% |
| 2017 | 75.7 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 57.6 Million CNY | 30.37% |
| 2024 Q3 | 37.06 Million CNY | -36.56% |
| 2024 Q1 | 44.18 Million CNY | -30.21% |
| 2023 Q2 | 35.5 Million CNY | -30.68% |
| 2023 FY | 179.16 Million CNY | -24.3% |
| 2023 Q4 | 63.31 Million CNY | 117.32% |
| 2023 Q3 | 29.13 Million CNY | -17.93% |
| 2023 Q1 | 51.21 Million CNY | -28.28% |
| 2022 Q3 | 47.28 Million CNY | 39.52% |
| 2022 Q2 | 33.88 Million CNY | -59.7% |
| 2022 Q1 | 84.08 Million CNY | 15.43% |
| 2022 FY | 236.66 Million CNY | 29.04% |
| 2022 Q4 | 71.41 Million CNY | 51.03% |
| 2021 FY | 183.4 Million CNY | 59.34% |
| 2021 Q4 | 72.84 Million CNY | 84.42% |
| 2021 Q3 | 39.49 Million CNY | 6.91% |
| 2021 Q2 | 36.94 Million CNY | 8.28% |
| 2021 Q1 | 34.12 Million CNY | 8.02% |
| 2020 FY | 115.1 Million CNY | 12.29% |
| 2020 Q4 | 31.58 Million CNY | -8.93% |
| 2020 Q3 | 34.68 Million CNY | 32.47% |
| 2020 Q2 | 26.18 Million CNY | 15.57% |
| 2020 Q1 | 22.65 Million CNY | 0.0% |
| 2019 FY | 102.5 Million CNY | 23.15% |
| 2018 FY | 83.23 Million CNY | 9.95% |
| 2017 FY | 75.7 Million CNY | 0.0% |